What's Happening?
Lannett Company, Lanexa Biologics, and Sunshine Lake Pharma have announced the FDA approval of LANGLARA, an interchangeable biosimilar to Lantus (insulin glargine). This approval allows pharmacists to substitute
LANGLARA for Lantus without prescriber intervention in states that permit such substitution. The approval was based on comprehensive analytical, preclinical, and clinical programs confirming the efficacy and safety of LANGLARA compared to Lantus. The biosimilar is manufactured by Sunshine Lake Pharma and will be commercialized in the U.S. through Lanexa Biologics, a subsidiary of Lannett Company.
Why It's Important?
The approval of LANGLARA is significant as it provides a more affordable treatment option for diabetes patients, potentially reducing the financial burden associated with insulin therapy. The interchangeability designation is crucial for patient access, reflecting the quality and scientific rigor of the product. This development could lead to broader formulary placement across commercial channels, enhancing accessibility for patients. The partnership between Lannett and Sunshine Lake Pharma highlights the importance of strategic collaborations in advancing biosimilar products and addressing healthcare needs.
What's Next?
Lannett and Lanexa Biologics plan to pursue broad formulary placement for LANGLARA across all commercial channels to ensure accessibility for patients. The companies are also collaborating on the development of a short-acting insulin aspart, which could further expand treatment options for diabetes patients. The acquisition of Lannett by Aurobindo Pharma is expected to close soon, with Lanexa becoming a stand-alone company, potentially impacting future strategic directions.
